Abstract
Hydroxyapatite (HA) has proven in recent years to be one of the most versatile and powerful methods for removing aggregates from antibody preparations. It is effective with IgA, IgG and IgM, and it reduces aggregate levels from above 60% to less than 0.1%. Three basic elution strategies have evolved, one that removes aggregates from a modest proportion of clones, another from the majority, and one that appears to be universally effective. Each has distinct development and process ramifications. This review defines what HA is, how it interacts with various classes of biomolecules, how those interactions are controlled by different elution strategies, and how to determine which approach may be most effective for a particular antibody. Consideration is also given to HAs specific strengths and limitations from an industrial perspective.
Current Pharmaceutical Biotechnology
Title: Antibody Aggregate Removal by Hydroxyapatite Chromatography
Volume: 10 Issue: 4
Author(s): Pete Gagnon and Kevin Beam
Affiliation:
Abstract: Hydroxyapatite (HA) has proven in recent years to be one of the most versatile and powerful methods for removing aggregates from antibody preparations. It is effective with IgA, IgG and IgM, and it reduces aggregate levels from above 60% to less than 0.1%. Three basic elution strategies have evolved, one that removes aggregates from a modest proportion of clones, another from the majority, and one that appears to be universally effective. Each has distinct development and process ramifications. This review defines what HA is, how it interacts with various classes of biomolecules, how those interactions are controlled by different elution strategies, and how to determine which approach may be most effective for a particular antibody. Consideration is also given to HAs specific strengths and limitations from an industrial perspective.
Export Options
About this article
Cite this article as:
Gagnon Pete and Beam Kevin, Antibody Aggregate Removal by Hydroxyapatite Chromatography, Current Pharmaceutical Biotechnology 2009; 10 (4) . https://dx.doi.org/10.2174/138920109788488833
DOI https://dx.doi.org/10.2174/138920109788488833 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiac Dysfunction in Rats with Dietary-Induced Insulin Resistance Associated with Pharmacologically-induced Dyslipidemia
Current Pharmaceutical Design Hydrolyzed Rutin Decreases Worsening of Anaplasia in Glioblastoma Relapse
CNS & Neurological Disorders - Drug Targets Antitumoral and Anticholinesterasic Activities of the Seven Species from Rubiaceae
Current Pharmaceutical Biotechnology Antidepressants: Current Strategies and Future Opportunities
Current Pharmaceutical Design Suicide Risk in Alzheimer’s Disease: A Systematic Review
Current Alzheimer Research Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine Improvement of Negative Symptoms in Schizophrenia: A Double-blind Clinical Trial by Escitalopram in Male Patients
Current Psychopharmacology Effects of Compounds from Passiflora edulis Sims f. flavicarpa Juice on Blood Coagulation and on Proteolytic Enzymes
Protein & Peptide Letters The Therapeutic Impact of New Migraine Discoveries
Current Medicinal Chemistry Phenothiazine: The Parent Molecule
Current Drug Targets Borderline Personality Disorder in Adolescents
Adolescent Psychiatry Patents on Brain Permeable Nanoparticles
Recent Patents on CNS Drug Discovery (Discontinued) Current Treatment Concepts of Philadelphia-Negative MPN
Current Cancer Drug Targets BX471: A CCR1 Antagonist with Anti-Inflammatory Activity in Man
Mini-Reviews in Medicinal Chemistry Pharmacokinetics and Tissue Distribution Study of Ferruginol in Wistar Rat by High-performance Liquid Chromatography
Current Pharmaceutical Analysis Apoptosis in Sepsis: Mechanisms, Clinical Impact and Potential Therapeutic Targets
Current Pharmaceutical Design Multi-Target Directed Compounds with Antioxidant and/or Anti- Inflammatory Properties as Potent Agents for Alzheimer’s Disease
Medicinal Chemistry Enriched Environment Prevents Cognitive Impairment and Tau hyperphosphorylation after Chronic Cerebral Hypoperfusion
Current Neurovascular Research Malaria-induced Alterations of Drug Kinetics and Metabolism in Rodents and Humans
Current Drug Metabolism The Role of Electroconvulsive Therapy (ECT) in Bipolar Disorder: Effectiveness in 522 Patients with Bipolar Depression, Mixed-state, Mania and Catatonic Features
Current Neuropharmacology